K-N. Chen
Peking University Cancer Hospital · 19 works · 285 citations · h-index 7
Top works
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
- Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
- 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
- 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
- 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
- LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671
- 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study
- 594P Perioperative nivolumab (NIVO) in patients (pts) with resectable stage II–IIIB NSCLC: CheckMate 77T Chinese population analysis
- LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup
- Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
- 903MO Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in patients (pts) with resectable epidermal growth factor receptor-mutated (EGFRm) stage II–IIIB non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from NeoADAURA
- 148P Neoadjuvant EGFR-TKI combined with chemotherapy improves the complete response rate in operable EGFR-mutant NSCLC patients: A multicenter real-world study
- EP.08.30 The Outcome of Preoprerative Therapy for Resectable NSCLC Patients With EGFR PACC Mutations
- 1243P Influence of home nutritional therapy on body weight in patients with esophageal cancer after surgery: A prospective observational study
- Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néoadjuvant (Tt néoadj) du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) dans l’essai de phase 3 CheckMate 816 (CM 816)
- Résultats chirurgicaux de l’essai de phase 3 CheckMate 816 (CM 816) : Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néo-adjuvant du cancer bronchique non à petites cellules (CBNPC) résécable
- Corrigendum to “LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671”
- 237P NeoADAURA: Positron emission tomography response criteria in solid tumors (PERCIST) outcomes following neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CTx) vs placebo (PBO) + CTx in patients (pts) with (w) resectable, EGFRm stage II–IIIB NSCLC